Clario bolsters executive leadership team to deliver on its long-term growth strategy
New CEO appoints two new executives and promotes senior scientist to new Chief Medical Officer position to focus company and help drive delivery of long-term growth strategy
- Terry Burke joins Clario as Executive Vice President of Clario’s eCOA business and David Fusco as Executive Vice President of Human Capital
- Dr. Todd Rudo, M.D. is promoted to the new role of Chief Medical Officer
- The appointments announced today fill a mix of new and existing roles, drawing on Clario’s internal talent and external expertise.
PHILADELPHIA, PA – October 6, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced three significant strategic changes to its executive leadership team to help focus the company and help drive delivery of long term growth strategy. The appointments fill a mix of new and existing roles, drawing on Clario’s internal talent and external expertise. Terry Burke joins Clario from Quest Diagnostics as Executive Vice President of Clario’s eCOA business, David Fusco joins Clario from Staple Street Capital as Executive Vice President of Human Capital, and Dr. Todd Rudo is promoted to the new role of Clario’s Chief Medical Officer.
Chris Fikry, Chief Executive of Clario, said:
‘As we focus on the changing and complex post-pandemic clinical trials environment, Clario continues to bring in the new skills and develop the existing talent we need to deliver for our clients and their patients. My colleagues and I are delighted to announce the latest additions to our leadership team, who will each bring deep expertise and broad experience to the business.’
Terry Burke
EVP eCOA
David Fusco
EVP & Chief Human Capital Officer
Dr. Todd Rudo
Chief Medical Officer
For more information or to schedule interviews with the new members of Clario’s executive leadership team, please contact [email protected].
About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.
For more information, go to Clario.com or follow us on LinkedIn.
Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]